Association between tumor necrosis factor inhibitor (TNFi) therapy and changes in C-reactive protein (CRP), blood pressure, and alanine aminotransferase (ALT) among patients with psoriasis, psoriatic arthritis, or rheumatoid arthritis

Saved in:
Bibliographic Details
Published inJournal of the American Academy of Dermatology Vol. 72; no. 5; pp. 917 - 919
Main Authors Wu, Jashin J., MD, Rowan, Christopher G., PhD, Bebchuk, Judith D., ScD, Anthony, Mary S., PhD
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.05.2015
Subjects
Alanine Transaminase - blood
Arthritis, Psoriatic - blood
Arthritis, Psoriatic - drug therapy
Arthritis, Rheumatoid - blood
Arthritis, Rheumatoid - drug therapy
Blood Pressure - drug effects
C-Reactive Protein - analysis
Cohort Studies
Dermatology
Humans
Methotrexate - therapeutic use
Middle Aged
Psoriasis - blood
Psoriasis - drug therapy
Retrospective Studies
Tumor Necrosis Factor-alpha - antagonists & inhibitors
Online AccessGet full text

Cover

More Information
Bibliography:SourceType-Other Sources-1
ObjectType-Article-2
content type line 63
ObjectType-Correspondence-1
ISSN:0190-9622
1097-6787
DOI:10.1016/j.jaad.2015.02.004